683 Capital Management LLC Takes Position in IN8bio, Inc. $INAB

683 Capital Management LLC purchased a new stake in shares of IN8bio, Inc. (NASDAQ:INAB) during the 4th quarter, Holdings Channel.com reports. The fund purchased 724,637 shares of the company’s stock, valued at approximately $1,696,000. 683 Capital Management LLC owned approximately 0.07% of IN8bio at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Captrust Financial Advisors bought a new position in shares of IN8bio during the 4th quarter valued at $43,000. Alyeska Investment Group L.P. lifted its holdings in shares of IN8bio by 1,060.8% during the 4th quarter. Alyeska Investment Group L.P. now owns 957,484 shares of the company’s stock valued at $2,231,000 after buying an additional 875,000 shares during the period. HRT Financial LP bought a new position in shares of IN8bio during the 4th quarter valued at $34,000. Franklin Resources Inc. lifted its holdings in shares of IN8bio by 381.6% during the 4th quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock valued at $2,048,000 after buying an additional 724,637 shares during the period. Finally, Texas Capital Bank Wealth Management Services Inc bought a new position in shares of IN8bio during the 4th quarter valued at $56,000. 92.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of IN8bio in a report on Tuesday, April 21st. HC Wainwright restated a “buy” rating on shares of IN8bio in a research note on Thursday, June 4th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, IN8bio presently has a consensus rating of “Hold” and a consensus target price of $4.00.

IN8bio Stock Performance

Shares of INAB stock opened at $1.47 on Thursday. IN8bio, Inc. has a 52-week low of $1.17 and a 52-week high of $2.73. The firm has a market capitalization of $14.48 million, a PE ratio of -0.56 and a beta of 0.19. The stock has a fifty day simple moving average of $1.53 and a two-hundred day simple moving average of $1.76.

IN8bio (NASDAQ:INAB) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.33. On average, sell-side analysts forecast that IN8bio, Inc. will post -1.53 EPS for the current fiscal year.

IN8bio Profile

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.